Weighted Average Number of Shares Outstanding, Basic of SAB Biotherapeutics, Inc. from 31 Dec 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
SAB Biotherapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Dec 2020 to 31 Dec 2025.
  • SAB Biotherapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 19,311,798, a 109% increase year-over-year.
  • SAB Biotherapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 19,311,798, a 109% increase from 2024.
  • SAB Biotherapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 9,261,918, a 68% increase from 2023.
  • SAB Biotherapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 5,521,487, a 27% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

SAB Biotherapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 19,311,798 +10,049,880 +109% 01 Oct 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 10,660,500 +1,401,308 +15% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 9,294,469 +39,444 +0.43% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 9,291,641 +49,701 +0.54% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 9,261,918 +3,740,431 +68% 01 Oct 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 9,259,192 +4,018,592 +77% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 9,255,025 +4,212,899 +84% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 9,241,940 +4,202,235 +83% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 5,521,487 +1,168,990 +27% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 5,240,600 -37,790,285 -88% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 5,042,126 -37,957,287 -88% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 5,039,705 -38,073,648 -88% 01 Jan 2023 31 Mar 2023 10-Q 20 May 2024 2024 Q1
Q4 2022 4,352,497 -22,986,683 -84% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 43,030,885 +17,057,479 +66% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 42,999,413 +17,026,007 +66% 01 Apr 2022 30 Jun 2022 10-Q 21 Aug 2023 2023 Q2
Q1 2022 43,113,353 +17,139,947 +66% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 27,339,180 01 Oct 2021 31 Dec 2021 10-K/A 28 Apr 2023 2021 FY
Q3 2021 25,973,406 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 25,973,406 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 25,973,406 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1

SAB Biotherapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 19,311,798 +10,049,880 +109% 01 Jan 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
2024 9,261,918 +3,740,431 +68% 01 Jan 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
2023 5,521,487 +1,168,990 +27% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 4,352,497 -22,986,683 -84% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 27,339,180 +1,948,096 +7.7% 01 Jan 2021 31 Dec 2021 10-K/A 28 Apr 2023 2021 FY
2020 25,391,084 01 Jan 2020 31 Dec 2020 10-K/A 28 Apr 2023 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.